US EditionPublished • loading... • Updated
Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy - PressReach
Summary by pressreach.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy - PressReach
Partner Orbicular receives ANDA approval from USFDA MUMBAI, India and WARREN, N.J., Feb. 27, 2026 /PRNewswire/ — Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as “Cipla”) today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single–patient–use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection). This milestone builds on the recent Abbrevi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
